Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1310/hpj5006-526

http://scihub22266oqcxt.onion/10.1310/hpj5006-526
suck pdf from google scholar
C4568114!4568114 !26405345
unlimited free pdf from europmc26405345
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26405345 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid26405345
      Hosp+Pharm 2015 ; 50 (6 ): 526-33
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Ceftolozane/Tazobactam #MMPMID26405345
  • Cada DJ ; Wageman J ; Baker DE ; Levien TL
  • Hosp Pharm 2015[Jun]; 50 (6 ): 526-33 PMID26405345 show ga
  • Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The June 2015 monograph topics are ceftazidime-avibactam, isavuconazonium sulfate, panobinostat, levodopa-carbidopa intestinal gel, and LCZ696. The Safety MUE is on ceftazidime-avibactam.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box